1. NAME OF THE MEDICINAL PRODUCT
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
3. PHARMACEUTICAL FORM
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
4.2 Posology and method of administration
4.3 Contraindications
4.4 Special warnings and precautions for use
[...]

Valdoxan provides MDD patients with a significant symptomatic relief, as demonstrated by well-documented improvements in depressed mood, anxiety symptoms, and also sleep-wake disturbances (daytime impairment and sleep disturbances).
Efficacy of Valdoxan on depressed mood
Valdoxan has been demonstrated to be significantly effective in relieving depressed mood of patients with MDD, the most characteristic symptom of depression.
In a [...]

Valdoxan’s antidepressant efficacy has been demonstrated in a large clinical program including 5 800 patients of whom 3 900 were treated with Valdoxan. The short-term efficacy of Valdoxan has been demonstrated over treatment periods of 6 to 12 weeks using standardized scales (Hamilton Depression Rating Scale [HAMD], Montgomery and Asberg Depression Rating Scale [MADRS], Clinical [...]